BACKGROUND: Unlike the tremendous progress made in atrial fibrillation ablation, the greatest unmet clinical need is for innovative ablation treatments for scar-related ventricular tachycardia (VT), particularly given the thick, often fibrotic tissue characteristic of the scarred substrate. A focal pulsed field ablation (PFA) catheter with a novel waveform was designed: high voltage to provide tissue penetration and low energy (using short-duration pulses) to avoid tissue overheating. We present the outcomes of VCAS (Ventricular Catheter Ablation Study), a first-in-human study of this PFA catheter to ablate scar-related VT. METHODS: An investigational 8.5F force-sensing PFA catheter was used for scar-VT ablation in ischemic or nonischemic substrates. Pulsed field lesions consisted of 5 applications, each <200 ms, of a high-voltage (>10 kV) monophasic waveform with QRS synchronization. The PFA catheter was localized by electrical impedance-based navigation. A subcohort of patients without previous cardiac surgery underwent epicardial ventricular mapping at baseline and after endocardial PFA to assess for transmurality of endocardial pulsed field lesions. Study end points included procedural efficiency, safety, and effectiveness to final follow-up of 6 months. RESULTS: At 2 centers, 26 patients underwent ablation: 66±9 years of age, 4% women, left ventricular ejection fraction 32±10%, VT storm 42%, previous VT ablation 42%. Acute procedural success, achieved in 24 (92%) patients, required 21 (interquartile range, 14-24) lesions per patient with a transpired ablation time of 31 minutes (19-42). Clinical VT was induced in 14 of 16 patients (88%) before ablation and 1 of 16 patients (6%, P<0.001) after ablation. High-density epi-endo voltage mapping was performed in 10 patients [42%]; of the 9 patients undergoing endocardial-only PFA, transmural tissue homogenization was observed in all 9 (100%) patients. Freedom from recurrent VT/ventricular fibrillation (VT/VF) or implantable cardioverter defibrillator shock was 81.8% (95% CI, 67.1-99.8). Regarding VT/VF burden, the incidence rate of postablation VT/VF significantly decreased from baseline to after PFA by 98% (median [IQR], 6 [1-11] versus 0 [0-0], respectively; P<0.001). Primary safety end points within 180 days occurred in 3 of 26 (11.5%) patients: cardiogenic shock, heart failure hospitalization, and retroperitoneal bleed. CONCLUSIONS: In this first-in-human study, the high-voltage PFA catheter efficiently delivered transmural ventricular lesions to treat scar-related VT. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT06203262.

Cardiology Department Homolka Hospital Prague Czech Republic

Cardiology Department Institute for Clinical and Experimental Medicine Prague Czech Republic

Helmsley Electrophysiology Center Mount Sinai Fuster Heart Hospital New York NY

Zobrazit více v PubMed

Cronin EM, Bogun FM, Maury P, Peichl P, Chen M, Namboodiri N, Aguinaga L, Leite LR, Al-Khatib SM, Anter E, et al. 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. Heart Rhythm. 2020;17:e2–e154. doi: 10.1016/j.hrthm.2019.03.002 PubMed PMC

Ciaccio EJ, Hsia HH, Saluja DS, Garan H, Coromilas J, Yarmohammadi H, Biviano AB, Peters NS. Ventricular tachycardia substrate mapping: what’s been done and what needs to be done. Heart Rhythm. 2025;22:2280–2299. doi: 10.1016/j.hrthm.2025.02.034 PubMed

Stevenson WG, Richardson TD, Kanagasundram AN, Tandri H. State of the art: mapping strategies to guide ablation in ischemic heart disease. JACC Clin Electrophysiol. 2024;10:2744–2761. doi: 10.1016/j.jacep.2024.09.016 PubMed

Dukkipati SR, Koruth JS, Choudry S, Miller MA, Whang W, Reddy VY. Catheter ablation of ventricular tachycardia in structural heart disease: indications, strategies, and outcomes-part II. J Am Coll Cardiol. 2017;70:2924–2941. doi: 10.1016/j.jacc.2017.10.030 PubMed

Anter E, Tschabrunn CM, Buxton AE, Josephson ME. High-resolution mapping of postinfarction reentrant ventricular tachycardia: electrophysiological characterization of the circuit. Circulation. 2016;134:314–327. doi: 10.1161/CIRCULATIONAHA.116.021955 PubMed PMC

Frontera A, Melillo F, Baldetti L, Radinovic A, Bisceglia C, D’Angelo G, Foppoli L, Gigli L, Peretto G, Cireddu M, et al. High-density characterization of the ventricular electrical substrate during sinus rhythm in post-myocardial infarction patients. JACC Clin Electrophysiol. 2020;6:799–811. doi: 10.1016/j.jacep.2020.04.008 PubMed

Nishimura T, Upadhyay GA, Aziz ZA, Beaser AD, Shatz DY, Nayak HM, Tung R. Circuit determinants of ventricular tachycardia cycle length: characterization of fast and unstable human ventricular tachycardia. Circulation. 2021;143:212–226. doi: 10.1161/CIRCULATIONAHA.120.050363 PubMed

Nishimura T, Shatz N, Weiss JP, Zawaneh M, Bai R, Beaser AD, Upadhyay GA, Aziz ZA, Nayak HM, Shatz DY, et al. Identification of human ventricular tachycardia demarcated by fixed lines of conduction block in a 3-dimensional hyperboloid circuit. Circulation. 2023;148:1354–1367. doi: 10.1161/circulationaha.123.065525 PubMed

Guichard J-B, Regany-Closa M, Vázquez-Calvo S, Zazu B, Pellicer, Sendra B, Serrano-Campaner J, Molero-Pereira S, Borràs R, Ortiz JT, Falzone PV, et al. Substrate mapping for ventricular tachycardia ablation through high-density whole-chamber double extra stimuli: the S3 protocol. JACC Clin Electrophysiol. 2024;10:1534–1547. doi: 10.1016/j.jacep.2024.04.023 PubMed

Chery G, Khoshknab M, Nazarian S. Imaging to facilitate ventricular tachycardia ablation: intracardiac echocardiography, computed tomography, magnetic resonance, and positron emission tomography. JACC Clin Electrophysiol. 2024;10:2277–2292. doi: 10.1016/j.jacep.2024.08.003 PubMed

Mohanty S, Trivedi C, Di Biase L, Burkhardt JD, Della Rocca DG, Gianni C, MacDonald B, Mayedo A, Shetty SS, Zagrodzky W, et al. Endocardial scar-homogenization with vs without epicardial ablation in VT patients with ischemic cardiomyopathy. JACC Clin Electrophysiol. 2022;8:453–461. doi: 10.1016/j.jacep.2021.12.011 PubMed

Koruth JS, Kuroki K, Iwasawa J, Viswanathan R, Brose R, Buck ED, Donskoy E, Dukkipati SR, Reddy VY. Endocardial ventricular pulsed field ablation: a proof-of-concept preclinical evaluation. Europace. 2020;22:434–439. doi: 10.1093/europace/euz341 PubMed PMC

Yavin HD, Higuchi K, Sroubek J, Younis A, Zilberman I, Anter E. Pulsed field ablation in ventricular myocardium using a focal catheter: the impact of application repetition on lesion dimensions. Circ Arrhythm Electrophysiol. 2021;14:e010375. doi: 10.1161/CIRCEP.121.010375 PubMed

Im SI, Higuchi S, Lee A, Stillson C, Buck E, Morrow B, Schenider K, Speltz M, Gerstenfeld EP. Pulsed field ablation of left ventricular myocardium in a swine infarct model. JACC Clin Electrophysiol. 2022;8:722–731. doi: 10.1016/j.jacep.2022.03.007 PubMed

Kawamura I, Reddy VY, Santos-Gallego CG, Wang BJ, Chaudhry HW, Buck ED, Mavroudis G, Jerrell S, Schneider CW, Speltz M, et al. Electrophysiology, pathology, and imaging of pulsed field ablation of scarred and healthy ventricles in swine. Circ Arrhythm Electrophysiol. 2023;16:e011369. doi: 10.1161/CIRCEP.122.011369 PubMed

Kawamura I, Reddy VY, Wang BJ, Dukkipati SR, Chaudhry HW, Santos-Gallego CG, Koruth JS. Pulsed field ablation of the porcine ventricle using a focal lattice-tip catheter. Circ Arrhythm Electrophysiol. 2022;15:e011120. doi: 10.1161/CIRCEP.122.011120 PubMed PMC

Pannone L, Doundoulakis I, Cespón-Fernández M, Eltsov I, Chierchia GB, de Asmundis C, Sarkozy A. A large footprint focal catheter toggling between pulsed field and radiofrequency energy: first clinical experience for ventricular tachycardia ablation. Europace. 2024;26:euae193. doi: 10.1093/europace/euae193 PubMed PMC

Peichl P, Wichterle D, Schlosser F, Stojadinović P, Nejedlo V, Borišincová E, Marek J, Štiavnický P, Hašková F, Kautzner J. Mapping and ablation of ventricular tachycardia using dual-energy lattice-tip focal catheter: early feasibility and safety study. Europace. 2024;26:euae275. doi: 10.1093/europace/euae275 PubMed PMC

Sacher F, Sarkozy A, Pürerfellner H, Steyer A, Lyne J, Coquard C, Tixier R, Combes N, Haissaguerre M, Efremidis M, et al. Safety and efficacy of a lattice-tip catheter for ventricular arrhythmia ablation: 1 the Affera Ventricular Arrhythmia Ablation ( PubMed PMC

Komatsu Y, Daly M, Sacher F, Cochet H, Denis A, Derval N, Jesel L, Zellerhoff S, Lim HS, Jadidi A, et al. Endocardial ablation to eliminate epicardial arrhythmia substrate in scar-related ventricular tachycardia. J Am Coll Cardiol. 2014;63:1416–1426. doi: 10.1016/j.jacc.2013.10.087 PubMed

Di Biase L, Burkhardt JD, Lakkireddy D, Carbucicchio C, Mohanty S, Mohanty P, Trivedi C, Santangeli P, Bai R, Forleo G, et al. Ablation of stable VTs versus substrate ablation in ischemic cardiomyopathy: the PubMed

Mohanty S, Trivedi C, Di Biase L, Burkhardt JD, Della Rocca DG, Gianni C, MacDonald B, Mayedo A, Shetty SS, Zagrodzky W, et al. Endocardial scar-homogenization with vs without epicardial ablation in VT patients with ischemic cardiomyopathy. JACC Clin Electrophysiol. 2022;8:453–461. doi: 10.1016/j.jacep.2021.12.011 PubMed

Tung R, Raiman M, Liao H, Zhan X, Chung FP, Nagel R, Hu H, Jian J, Shatz DY, Besser SA, et al. Simultaneous endocardial and epicardial delineation of 3d reentrant ventricular tachycardia. J Am Coll Cardiol. 2020;75:884–897. doi: 10.1016/j.jacc.2019.12.044 PubMed

Stevenson WG, Richardson TD, Kanagasundram A. Ventricular tachycardia in 3 dimensions. J Am Coll Cardiol. 2020;75:898–900. doi: 10.1016/j.jacc.2019.12.045 PubMed

Moss AJ, Greenberg H, Case RB, Zareba W, Hall WJ, Brown MW, Daubert JP, McNitt S, Andrews ML, Elkin AD; Multicenter Automatic Defibrillator Implantation Trial-II (MADIT-II) Research Group. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation. 2004;110:3760–3765. doi: 10.1161/01.CIR.0000150390.04704.B7 PubMed

Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH, Reddy RK, Marchlinski FE, Yee R, Guarnieri R, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008;359:1009–1017. doi: 10.1056/NEJMoa071098 PubMed PMC

MacIntyre CJ, Sapp JL, Abdelwahab A, Al-Harbi M, Doucette S, Gray C, Gardner MJ, Parkash R. The effect of shock burden on heart failure and mortality. CJC Open. 2019;1:161–167. doi: 10.1016/j.cjco.2019.04.003 PubMed PMC

Samuel M, Elsokkari I, Sapp JL. Ventricular tachycardia burden and mortality: association or causality? Can J Cardiol. 2022;38:454–464. doi: 10.1016/j.cjca.2022.01.016 PubMed

Samuel M, Healey JS, Nault I, Sterns LD, Essebag V, Gray C, Hruczkowski T, Gardner M, Parkash R, Sapp JL. Ventricular tachycardia and ICD therapy burden with catheter ablation versus escalated antiarrhythmic drug therapy. JACC Clin Electrophysiol. 2023;9:808–821. doi: 10.1016/j.jacep.2023.01.030 PubMed

Elsokkari I, Parkash R, Tang A, Wells G, Doucette S, Yetisir E, Gardner M, Healey JS, Thibault B, Sterns L, et al. Mortality risk increases with clustered ventricular arrhythmias in patients with implantable cardioverter defibrillators. JACC Clin Electrophysiol. 2020;6:327–337. doi: 10.1016/j.jacep.2019.11.012 PubMed

Samuel M, Healey JS, Nault I, Sterns LD, Essebag V, Gray C, Hruczkowski T, Gardner M, Parkash R, Sapp JL. Ventricular tachycardia and ICD therapy burden with catheter ablation versus escalated antiarrhythmic drug therapy. JACC Clin Electrophysiol. 2023;9:808–821. doi: 10.1016/j.jacep.2023.01.030 PubMed

US FDA Premarket Approval Application (PMA) Number: P110016/S080. 2022. Accessed July 30, 2025. https://www.accessdata.fda.gov/cdrh_docs/pdf11/P110016S080B.pdf

Sapp JL, Tang ASL, Parkash R, Stevenson WG, Healey JS, Gula LJ, Nair GM, Essebag V, Rivard L, Roux JF, et al. ; VANISH2 Study Team. Catheter ablation or antiarrhythmic drugs for ventricular tachycardia. N Engl J Med. 2025;392:737–747. doi: 10.1056/NEJMoa2409501 PubMed

Ekanem E, Neuzil P, Reichlin T, Kautzner J, van der Voort P, Jais P, Chierchia GB, Bulava A, Blaauw Y, Skala T, et al. Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the PubMed PMC

Reddy VY, Petru J, Funasako M, Kopriva K, Hala P, Chovanec M, Janotka M, Kralovec S, Neuzil P. Coronary arterial spasm during pulsed field ablation to treat atrial fibrillation. Circulation. 1808;146:1808–1819. doi: 10.1161/circulationaha.122.061497 PubMed

Malyshev Y, Neuzil P, Petru J, Funasako M, Hala P, Kopriva K, Schneider C, Achyutha A, Vanderper A, Musikantow D, et al. Nitroglycerin to ameliorate coronary artery spasm during focal pulsed-field ablation for atrial fibrillation. JACC Clin Electrophysiol. 2024;10:885–896. doi: 10.1016/j.jacep.2023.12.015 PubMed

Reddy VY, Gerstenfeld EP, Schmidt B, Andrade JG, Nair D, Natale A, Saliba W, Sommer P, Metzner A, Verma A, et al. ; ADVANTAGE AF Investigators. Pulsed field ablation of persistent atrial fibrillation with continuous ECG monitoring follow-up: ADVANTAGE AF-Phase 2. Circulation. 2025;152:27–40. doi: 10.1161/CIRCULATIONAHA.125.074485 PubMed PMC

Nair D, Gabrah K, Doty B, Nair G, Reddy VY. Cardiac implantable electronic device software reset and damage following pulsed field ablation using a monopolar lattice-tip catheter [published online October 7, 2025]. Heart Rhythm. 2025:S1547-5271(25)02920-0. doi: 10.1016/j.hrthm.2025.09.027 PubMed

Zobrazit více v PubMed

ClinicalTrials.gov
NCT06203262